Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

Fact checked byHeather Biele

AiViva Biopharma announced that it has completed enrollment and dosing of the last patient in a phase 1 clinical trial of AIV007 for wet age-related macular degeneration and diabetic macular edema.

“AIV007 (lenvatinib) is a broad-spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis and inflammation,” Diane Tang-Liu, PhD, AiViva’s CEO, president and co-founder, said in a company press release. “We believe AIV007, formulated with our proprietary JEL technology and administered periocularly, has the potential to address the root causes of wet AMD, DME and many other ocular diseases.”

eyes — AIV007 is tyrosine kinase inhibitor administered via periocular injection for treatment of AMD and DME. *Image: Adobe Stock*

The multicenter, open-label, dose-escalation safety trial enrolled 18 participants, who received a single periocular injection of AIV007 and will be evaluated monthly for up to 6 months.

The company plans to have the study completed, with full results available, in the first quarter of 2025, the release stated.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

Related Content